Denmark's Stenocare Q4 net sales double

StenoCare A/S

26/02/2026 07:11

Overview

Denmark medical cannabis supplier's Q4 net sales rose 107% yr/yr

Company achieved positive EBITDA for third consecutive quarter

Company acquired CannGros ApS, adding DKK 4-6 mln in annual revenue

Outlook

Stenocare expects CannGros acquisition to add DKK 4-6 mln in annual revenue

Company aims for break-even in 2026 supported by CannGros acquisition

Stenocare plans to launch Astrum Oil in Germany by Feb 2026

Result Drivers

STRATEGIC INVESTMENTS - Co exited Danish cultivation facility and acquired CannGros ApS, contributing to sales growth and future profitability

COST MANAGEMENT - Co reduced external expenses by 13% and personnel expenses by 37% in Q4 compared to Q4-2024

SALES GROWTH - Q4 sales increased by 36% over Q3-2025 and 107% over Q4-2024

Company press release: ID:nWkr7SP78t

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Sales
DKK 2.61 mln
Q4 EPS
DKK 0
Q4 EBITDA
DKK 12,000


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)